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Eplerenone (EP 1 ; Fig. 1 ) is methyl hydrogen 9,11␣-epoxy-17␣-hydroxy-3-oxopregn-4-ene-7␣,21-dicarboxylate,␥-lactone and a highly selective aldosterone blocker (McMahon, 2001) . EP has been approved for the treatment of hypertension in the United States, and a New Drug Application for treatment of heart failure has been filed in the United States in 2003. Blockade of aldosterone is known to be beneficial in the treatment of cardiovascular and renovascular diseases. Although angiotensin-converting enzyme inhibitors block the renin-angiotensin-aldosterone system, the reduction in aldosterone is only partial and transient, leaving the potentially deleterious effects of aldosterone unchecked. Spironolactone, a nonselective aldosterone blocker, is effective in suppressing the actions of aldosterone. In the Randomized Aldactone Evaluation Study (RALES), addition of spironolactone to standard therapy reduced mortality rates by 30% in patients with severe heart failure caused by systolic left ventricular dysfunction (Pitt et al., 1999) . However, it is associated with progestational and antiandrogenic side effects due to its promiscuous binding to other steroid receptors (Sun et al., 1997; Pitt et al., 1999) . To avoid these side effects, a new, highly selective aldosterone blocker, EP, has been developed. The presence of a 9,11-epoxide group in the EP molecule dramatically reduced progestational and antiandrogenic side effects compared with spironolactone, while maintaining aldosteroneblocking activity (McMahon, 2001) . In a 12-month clinical trial of 499 patients with mild to moderate hypertension, systolic and diastolic blood pressures were reduced from baseline by 14.5 and 11.2 mm Hg for patients treated with EP, whereas the blood pressures were reduced by 12.7 and 11.3 mm Hg, respectively, for patients treated with enalapril (Liew et al., 2003) . The Eplerenone Postacute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) of which primary end points were death from any cause and death or hospitalization from cardiovascular causes found a significant 15% relative reduction in all-cause mortality and 13% relative reduction in the combined endpoint of cardiovascular death and hospitalizations among the patients treated with EP, compared with patients on standard therapy (Pitt et al., 2003) . Because of this proven efficacy and aldosterone selectivity, EP is expected to provide important clinical benefits not previously available with spironolactone. The present study was conducted to investigate absorption, distribution, metabolism and elimination of EP in humans after oral administration of [ 14 C]EP.
termine the absorption, distribution, metabolism, and elimination of orally administered [
14 C]EP. The study was designed as an open-label, single-dose study with eight subjects. Eligible subjects were chosen on the bases of a pretreatment screen of relevant parameters including medical history, physical examination, vital signs, 12-lead electrocardiogram, hepatitis B surface antigen test, hepatitis C antibody test, human immunodeficiency virus (HIV) test, drug/alcohol tests, and a number of clinical laboratory tests monitoring for hematology, biochemistry, and urinalysis. These parameters were determined during the subject selection process and then, again (excluding hepatitis and HIV tests), 24 h before administration of the study medication. The clinical and pharmacokinetic portions of the study were conducted in compliance with the institutional review board regulations in This was combined at room temperature with 60 ml of commercially purchased apple juice. After the apple juice/hydroxypropyl-betacyclodextrin/ [ 14 C]EP solution was administered to the subject, the bottle was rinsed with an additional 60 ml of apple juice. The rinse was then administered to the subject.
Blood, saliva, breath, urine, and fecal samples were collected at predetermined intervals before and after the administration of [
14 C]EP. Samples from all matrices were analyzed for concentrations of total radioactivity using a validated liquid scintillation counting (LSC) procedure. For the LSC procedure, the shapes of all quench curves were good for all matrices and the quench range was sufficient for all samples. The 14 C counting efficiency of the liquid scintillation analyzer varied between 95.8% and 96.8%, and the background varied between 19.6 and 22.3 dpm. Before analysis by LSC, fecal samples were combusted on a biological oxidizer. The mean (ϮS.D.)
14 C combustion recovery of the oxidizer was 98.3 Ϯ 0.9%, the mean 14 C carryover was 0.19 Ϯ 0.10%, and the mean correction factor was 1.05 Ϯ 0.03. EP and EPA concentrations were also quantified using a liquid chromatography-tandem mass spectrometric (LC/MS-MS) assay validated for their determination in plasma and urine. The sensitivity for the LC/MS-MS assays in the plasma and urine was 10 ng/ml and 50 ng/ml, respectively.
Plasma Protein Binding. The in vitro plasma protein binding of [ 14 C]EP was determined in whole blood obtained in heparinized BD Vacutainer tubes with plasticizer-free rubber stoppers (BD Biosciences-Discovery Labware, Bedford, MA) from four healthy male subjects 20 to 60 years old. The subjects were fasted overnight and had no drug intake for at least 6 days. The binding was determined by an ultrafiltration method as follows. [
14 C]EP was added to plasma or 0.1 M phosphate buffer (pH 7.4) to achieve the final concentrations of 0.02, 0.2, 1, 5, and 60 g/ml. Plasma samples were filtered through a CentriFree filtration device (Millipore Corporation, Bedford, MA) at 1,000g for 1 h at 25°C. Triplicate aliquots (0.8 ml) of the buffer sample at each concentration also were centrifuged under the same conditions for 15 min. Approximately 0.2 to 0.4 ml of filtrate was collected from each device and total radioactivity in the filtrate was determined by LSC.
Plasma protein binding was also determined in the clinical study, following an oral dose of [ 14 C]EP. Plasma samples from 1.5 h postdose were also filtered through the CentriFree filtration device using the same filtration method as described above. The filtrate was collected and total radioactivity was measured by LSC. In each case, the fraction of radioactivity bound in plasma was obtained by the following equation:
where [D] F is the drug concentration in the filtrate and [D] T is the concentration in plasma or buffer. Metabolic Profiles of Plasma, Urine, and Fecal Samples. The representative distribution profiles of radioactivity in pooled plasma, urine, and fecal samples were determined as follows using high performance liquid chromatography (HPLC) with radiochemical detection.
Plasma samples were prepared by precipitating plasma proteins with a volume of acetonitrile equal to that of the plasma aliquot from each subject (400 l), vortexing briefly, and centrifuging. The supernatants were combined, evaporated to dryness under a stream of nitrogen, reconstituted in 10% aqueous acetonitrile, with or without acidifying with 20% (v/v) 1 N HCl, and injected onto the HPLC system described below.
Greater than 90% of the radioactivity excreted in urine was excreted within the first 48 h. Therefore, aliquots of samples collected up to 48 h were pooled proportionately by volume. An aliquot, 600 l, of the pooled urine was evaporated to dryness under a stream of nitrogen, reconstituted in 10% aqueous acetonitrile, with or without acidifying with 20% (v/v) 1 N HCl, centrifuged, and injected onto the HPLC system.
Greater than 90% of the radioactivity in feces was excreted within 96 h. Portions of the fecal samples collected over the first 96 h were pooled proportionately by weight. Approximately 1.5 g of pooled fecal sample were extracted with 10 ml of acetonitrile by end-over-end rotation for 1 h in a polypropylene centrifuge tube using a rotating mixer. The extract was centrifuged at 1,900g for 10 min at 4°C. The supernatant was transferred to a new tube. The pellet was re-extracted as described above and the supernatants were combined. The extract was evaporated to dryness under a stream of nitrogen, reconstituted in 10% aqueous acetonitrile, with or without acidifying with 20% (v/v) 1 N HCl, centrifuged, and injected onto the HPLC system. Processed plasma, urine, and fecal samples were analyzed for radioactivity distribution on an HP1050 HPLC system (Agilent Technologies, Inc., Palo Alto, CA) using 5-m Alltima C18 guard (7.5 ϫ 4.6 mm) and analytical (150 ϫ 4.6 mm) columns (Alltech Associates, Deerfield, IL). A linear gradient of 10% aqueous acetonitrile to 50% aqueous acetonitrile over 40 min at a flow rate of 1 ml/min was used. Radioactivity eluting from the column was detected by a Flo-One Radiomatic detector (Flo-One/␤ A-500; PerkinElmer Instruments, Norwalk, CT).
Percentage of dose excreted as each metabolite in urine and feces was calculated by multiplying the percentage of the eluting radiochromatographic peak by the fraction of radioactivity excreted in urine or feces, as appropriate.
Metabolite Identification. Metabolites corresponding to the radioactive peaks eluting in metabolic profiles of urine and feces were identified by LC/MS-MS and nuclear magnetic resonance spectroscopy (NMR). Metabolites in plasma were identified by comparison with urinary and fecal profiles.
FIG. 1. Chemical and enzymatic conversion between EP and EPA.
The asterisk indicates the position of the labeled carbon atom.
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Metabolites were isolated by separation on an HPLC system similar to that described above. Urine and fecal samples from the [
14 C]EP clinical study were prepared as scaled-up versions of those used in the radiochromatographic profiling. Repetitive injections were made on the HPLC system while 30-s fractions were collected from the column eluate. When sufficient quantities of each metabolite peak were collected, each metabolite was profiled on the above HPLC system with radiochemical detection to check for purity. The metabolites were further purified on the HPLC system with fraction collection, as necessary, for analysis by LC/MS-MS and NMR.
The LC/MS-MS conditions were designed to determine the mol. wt. and the unique fragmentation pattern of each metabolite. The HP1050 LC system employed a 3.5-m Zorbax SB-C18 analytical column (150 ϫ 3.0 mm) (Agilent Technologies) at 50°C. A linear gradient was used, consisting of 5% aqueous methanol, 12.5 mM ammonium acetate to 95% aqueous methanol, 12.5 mM ammonium acetate over 30 min followed by a 10-min hold. LC/ MS-MS data were obtained on a Finnigan TSQ700 MS system using the Finnigan APCI source and interface. The APCI source and interface were operated with the following conditions: the sprayer temperature was 500°C, the capillary temperature was 200°C, the sheath flow was 10 ml/min N 2 , the nebulizing gas pressure was 80 psi, and the source offset was Ϫ15 V. Positive-ion LC/MS-MS spectra were recorded using an argon collision gas pressure of 0.4 mTorr and a collision-energy of 30 V. Also, electron impact mass spectra for each metabolite were obtained by desorption probe induction on a Finnigan MAT8430 mass spectrometry system at 70 eV and a 250°C source temperature.
The NMR spectra of the fecal metabolites were determined using solutions in D 3 -acetonitrile, a 2.5-mm triple gradient indirect detection probe, and a Bruker DRX-600 MHz instrument (Bruker Biospin; Bruker Instruments Inc., Billerica, MA). The NMR spectra of the urinary metabolites were determined using solutions in D 3 -acetonitrile placed in 2.5-mm concentric tubes, a 5-mm single-gradient indirect detection probe, and a Bruker AMX-500 MHz instrument. The samples were placed under high vacuum before dissolving in D 3 -acetonitrile. The assignment of all the proton and carbon-13 chemical shifts for the parent drug, EP, in CD 3 CN solution were made by analyzing the one-dimensional proton and carbon-13 NMR spectra, and the two-dimensional COSY, heterocorrelation, transverse rotating frame nuclear Overhauser enhancement spectroscopy, heteronuclear multiple quantum coherence spectroscopy, and heteronuclear multiple-bond correlation spectroscopy data. The structures of the metabolites are based on the mass spectral data, on the changes in the proton NMR signals as determined by direct comparison with the corresponding signals observed for EP, and on the COSY data.
Pharmcokinetic Analysis. The observed peak plasma concentrations (C max ) of total radioactivity, EP, and EPA, and time to reach peak plasma concentrations (T max ) were obtained for each subject. The areas under the plasma concentration-time curve (AUCs) were calculated using the linear trapezoidal rule. Concentration-time curves of EP and EPA in plasma and amounts of EP and EPA excreted in urine after oral administration were simultaneously fit according to the pharmacokinetic model (Fig. 2) using the SAAM II computer program (SAAM Institute, Seattle, WA). The differential equations for the proposed pharmacokinetic model are given in eqs. 2 through 6.
Upon integration of the above equations, plasma concentrations of EP (C B ) and EPA (C C ) can be described by eqs. 7 and 8, respectively, and the amounts of EP (D) and EPA (E) in the urine can be described by eqs. 9 and 10, respectively.
where k ϭ k 20 ϩ k 23 ϩ k 24.
Results

EP Concentrations and Pharmacokinetics. After oral administration of [
14 C]EP at a dose of 100 mg per person, mean C max and AUC values of total radioactivity in plasma were higher than those in whole blood (Table 1) . Over time, the blood to plasma ratio of total radioactivity was constant, ranging from 0.70 to 0.78 (Fig. 3) . These results suggest that binding of total drug-related materials to plasma is greater than red blood cell partitioning, and total radioactivity was not preferably partitioned into red blood cells. The C max values of total radioactivity in saliva were similar to those in plasma, whereas saliva T max was much shorter than that in plasma. However, T max and C max are predominantly influenced by residual radioactivity in the mouth after administration of the radioactive dose solution. Saliva to plasma and saliva to blood ratios of total radioactivity were 0.35 to 0.42 and 0.45 to 0.52, respectively, and were relatively constant 2 h or later after the oral dose. Low saliva concentrations of total radioactivity, relative to plasma or blood concentrations, were most likely due to the equilibrium of only unbound drug and metabolites between blood and saliva. Mean (ϮS.D.) C max of EP was 1.72 Ϯ 0.28 g/ml, and the mean T max was 1.3 Ϯ 0.8 h ( Table 1) . The corresponding values for EPA were 0.083 Ϯ 0.017 g/ml and 1.1 Ϯ 0.3 h, respectively. The mean AUC for EP and EPA were 9.54 Ϯ 3.20 and 0.352 Ϯ 0.115 g ⅐ hr/ml, respectively. Plasma concentration and amounts of EP and EPA excreted in urine were simultaneously fitted according to the pharmacokinetic model presented in Fig. 2 . The mean experimental and simulated values for EP and EPA are shown in Fig. 4 . The mean t 1/2 values for absorption (k 12 ) phase and total elimination (k, sum of k 20 , k 23 , and k 24 ) phase were 3.01 and 0.26 h, respectively (Table 2) . Thus, the apparent elimination half-life of 3 h appears to be due to slow absorption of the drug. EPA was much more rapidly eliminated in urine compared with EP, and its elimination rate constant (k 35 ) was approximately 180-fold greater than that of EP (k 24 ).
Plasma Protein Binding. The plasma protein binding of EP was moderate but concentration-dependent over the concentration range of 0.02 g/ml to 60 g/ml. At concentrations of 0.02 g/ml, 0.2 g/ml, 1.0 g/ml, 5.0 g/ml, and 60 g/ml, the percentages of [ 14 C]EP bound were 60.6 Ϯ 5.2%, 59.0 Ϯ 6.2%, 38.2 Ϯ 4.8%, 33.3 Ϯ 4.2%, and 16.8 Ϯ 2.4%, respectively. The percentage of protein binding in the concentration range at the therapeutic dose (0.02-5.0 g/ml) was approximately 60 to 33%. However, in the clinical study, the percentage bound of total radioactivity at 1.5 h postdose (mean concentration of 2.36 g Eq/ml) was 49.6 Ϯ 12.7%. Since the majority (Ͼ90%) of total radioactivity in these plasma samples was due to the parent drug, this value is expected to reflect plasma protein binding of [ 14 C]EP in these subjects. Therefore, the plasma protein binding data obtained in the clinical study appeared to be slightly higher than those obtained 
FIG. 4. Plasma concentrations of EP and EPA (A) and cumulative percentage of dose excreted in urine as EP and EPA (B).
Circles indicate EP. Triangles indicate EPA. Data points are actual mean values Ϯ standard error of the mean. Solid lines are the model-simulated curves. in the in vitro study. The exact reason for this discrepancy is not known. However, one possibility is that the extent of binding of EP was different among the individuals. The other possibility is that the protein binding of metabolites was higher than that of EP, although the metabolites were present in much smaller amounts.
Metabolic Profiles. The HPLC chromatograms of plasma (acetonitrile extracts), urine, and feces (acetonitrile extracts) with acidification are shown in Fig. 5 . When plasma, urine, and fecal samples were acidified, the percentages associated with the parent drug increased slightly compared with those without acidification (data not shown). This was due to cyclization of the lactone ring open form, EPA, under mildly acidic conditions. The majority of radioactivity in 1.5-h plasma was due to the parent drug. In plasma, the 6␤-hydroxy metabolite was the major metabolite, and small amounts of 6␤,21-hydroxy, 3␣,6␤-hydroxy, and 21-hydroxy metabolites were present. In urine, 6␤-OHEP and 6␤,21-OHEP were major metabolites. Small amounts of the 3␣,6␤,21-hydroxy, 6␤,15␣-hydroxy, 3␣,6␤-hydroxy, and 21-hydroxy metabolites, and the parent drug were also present in the urine. In feces, more than 11 metabolite peaks were observed. The highest radioactive peak was associated with 6␤,21-OHEP. The other radioactive peaks present in feces were 3␤,6␤,21-OHEP, 2␣,3␤,6␤-OHEP, 3␣,6␤,21-OHEP, 6␤,15␣-OHEP, 3␤,6␤-OHEP, 3␣,6␤-OHEP, 6␤-OHEP, 21-OHEP, and EP. Details of identification of these metabolites are described below.
Identification of Metabolites. The structures proposed for each of the metabolite peaks in urinary and fecal profiles are shown in Fig. 6 . Table 3 shows the HPLC radiochromatographic retention time, mass spectral, and 1 H NMR data of EP and its metabolites. Electron impact mass spectra (not shown) gave intense molecular ions for all metabolites except peak 6. LC/MS-MS using APCI gave either the ammonium adduct, MNH 4 ϩ , the protonated molecular ion, MH ϩ , or both. From these data the mol. wt. was obtained for each metabolite (Table  3 for APCI). In this series of metabolites, the mol. wt. permitted the immediate assessment of the extent and nature of the metabolism. The general approach that was used in establishing the structures of the metabolites shown in Fig. 6 is briefly described below. The proposed structures of all metabolites were fully consistent with the mass spectral data and all proton NMR data.
The NMR spectra of all metabolites showed the same pattern for the C-11 and C-12 protons, thus indicating that the epoxide group was unchanged. The NMR spectrum of all the metabolites had a singlet at (5) 5.56d J 2.1 (C-4) ; 4.45d J 2.6 (C-6␣); 3.74dd J 6.5, 2.2 (C-3); 3.54s (-OCH 3 ); 3.42ddd J 9.7, 6.51 4.1 (C-2␤); 3.14 d J 5.4 (C-11); 2.86dd J 11.0, 5.0 (C-8); 2.74dd J 4.9, 2.3 (C-7); 1.79d J 15.3 (C-12␣); 1.65dd J 14.6, 5.5 (C-12␤); 1.59dd J13.9, 4.1 (C-1␤); 1.01dd J 13.9, 9.7 (C-1␣); 1.45s ( 203(11), 195(5), 163(35), 121(6) about 3.6 ppm that was assigned to the methyl ester protons, indicating that all the metabolites retained the methyl ester.
Hydroxylation at the C-6␤ position was indicated by the appearance of a doublet near 4.5 ppm (J ϭ 2.1) and changes in the patterns due to the C-7 and C-8 protons. In those compounds in which the C-3 ketone was not reduced, hydroxylation at C-6␤ also caused a significant downfield shift of the C-19 methyl proton signal. In this respect, peaks 2, 3, 4, 5, 6, 7, 8, and 9 were identified as having a C-6␤-hydroxyl group. Peak 9 (mol. wt. of 430) has simply a 6␤-hydroxyl group added to the structure of EP. Therefore, peak 9 was identified as 6␤-OHEP.
Hydroxylation at C-21 caused a decrease in the chemical shift difference between the two C-12 protons and the appearance of a single proton doublet of doublets near 4.4 ppm (J ϭ 10, 8.8 Hz). Based on these criteria, peaks 2, 4, 6, and 10 were assigned as C-21 hydroxylated derivatives. Peak 10 (mol. wt. of 430) has simply a 21-hydroxyl group added to the structure of EP. Therefore, peak 10 was identified as 21-OHEP. Peak 6 (mol. wt. of 446) has both a 6␤-hydroxyl group and a 21-hydroxyl group added. Therefore, peak 6 was identified as 6␤,21-OHEP. However, the proton spectrum of peak 6 had two signals (0.928 and 0.902 ppm) in the region expected for a single C-18 methyl signal, and an apparent quartet rather than a triplet in the 4.4 ppm region. The apparent quartet in the 4.4 ppm region was, in fact, composed of two overlapping triplets. These observations were interpreted as showing that peak 6 consisted of a mixture of the two C-21 stereoisomers.
The C-4H signal of several C-6␤-hydroxyl metabolites was split either by a 2.0-Hz (peaks 2, 3, and 7) or a 4.5-Hz (peaks 4 and 8) coupling with C-3H. These couplings and the additional two hydrogen atoms demonstrate that the C-3 carbonyl in each of these metabolites has been reduced to the hydroxyl group. In the case of the 2.0-Hz coupling, the hydroxyl group was determined to be in the ␤, or equatorial, configuration. In the case of the 4.5-Hz coupling, the hydroxyl group was determined to be in the ␣, or axial, configuration. Peaks 7 and 8 (mol. wt. of 432) each have a 6␤-hydroxyl group as well as the reduced C-3 carbonyl group with isomeric configuration at the C-3 position. Thus, these peaks were identified as 3␤,6␤-OHEP and 3␣,6␤-OHEP, respectively. Peaks 2 and 4 (mol. wt. of 448) each had C-6␤-hydroxyl and C-21 hydroxyl groups as well as the reduced C-3 carbonyl group with isomeric configuration at the C-3 position. Thus, peaks 2 and 4 were identified as 3␤,6␤,21-OHEP and 3␣,6␤,21-OHEP, respectively.
Peak 3 had a C-6␤ hydroxyl group and a C-3␤ hydroxyl group, as well as an additional hydroxyl group as shown by an MNH 4 ϩ peak at m/z 466 and the overlapping doublet of doublets of doublets near 3.4 ppm in the NMR spectrum. The position of the additional hydroxyl group could be deduced by noting in the COSY that the proton with the signal near 3.4 ppm is coupled to the C-3 proton, and hence must be located at C-2. The ␤ configuration of the C-2 hydroxyl group was established by the large coupling (9.7 Hz) between the C-2H and C-1␣H. Therefore, peak 3 was identified as 2␣,3␤,6␤-OHEP.
Peak 5 has a C-6␤ hydroxyl group and an additional hydroxyl group, resulting in a molecular weight of 446. The patterns of C-1H, C-6H, and C-11H and the chemical shift difference between the C-12Hs were unchanged from the patterns observed for EP. Therefore, the additional hydroxylation cannot be in rings A, B, D, or E. The remaining possibilities were for the hydroxyl group to be located at C-15 or C-16. The signal due to the proton attached to the carbon bearing the second hydroxyl group was split into an overlapping doublet of doublet of doublets with coupling constants of 9.5, 7.4, and 2.4 Hz. This means that there probably are at least three protons on the adjacent carbon atoms. The two large couplings require that the proton on the hydroxylated carbon is pseudoaxial; thus, peak 5 was identified as 6␤,15␣-OHEP.
Finally, the structure of peak 12 was shown by the HPLC retention time and mass spectral data to be the parent compound, EP. The quantities of peak 1 and 11 isolated from fecal samples were too small to permit determination of masses by LC-MS/MS or structures by NMR.
Excretion. The mean (ϮS.D.) percentages of the dose excreted as total radioactivity in urine and feces were 66.6 Ϯ 3.11% and 32.0 Ϯ 3.68%, respectively (Fig. 7) . The majority of urinary radioactivity was excreted within the first 24 h, indicating rapid elimination of the drug and metabolites. Although plasma concentrations of EPA were lower than EP concentrations (Fig. 4) , mean EPA excreted in urine (4.98 Ϯ 1.50%) was greater than that of EP (1.65 Ϯ 0.28%). Approximately 28% of the dose was excreted as 6␤-OHEP and 13% of the dose was excreted as 6␤,21-OHEP in urine (Table 4) . The percentages of all the other metabolites excreted in urine were approximately 5% of the dose or less. The percentage of the dose excreted as total EP (EP plus EPA) in urine was 6.8% using radioactive assay, and this was consistent with the value obtained from the LC-MS/MS assay (6.6%). The percentages of EP and EPA in feces were 0.81 Ϯ 0.44 and 1.65 Ϯ 0.77%, respectively. The percentages of dose excreted as 3␣,6␤,21- 
